Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy al...

Descripción completa

Detalles Bibliográficos
Autores principales: Borch, Troels Holz, Andersen, Rikke, Ellebaek, Eva, Met, Özcan, Donia, Marco, Marie Svane, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398110/
https://www.ncbi.nlm.nih.gov/pubmed/32747469
http://dx.doi.org/10.1136/jitc-2020-000668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398110/
https://www.ncbi.nlm.nih.gov/pubmed/32747469
http://dx.doi.org/10.1136/jitc-2020-000668

Ejemplares similares